Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Investment Securities (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has disclosed Gains from Investment Securities for 11 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 12.32% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, up 12.32%, while the annual FY2025 figure was $13.1 million, 12.32% up from the prior year.
  • Gains from Investment Securities hit $13.1 million in Q4 2025 for Syndax Pharmaceuticals, up from $11.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $17.0 million in Q4 2022 and bottomed at $7778.0 in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $4.2 million, with a median of $1.7 million recorded in 2021.
  • Year-over-year, Gains from Investment Securities tumbled 99.69% in 2022 and then skyrocketed 3866.96% in 2023.
  • Syndax Pharmaceuticals' Gains from Investment Securities stood at $2.5 million in 2021, then surged by 580.0% to $17.0 million in 2022, then crashed by 93.53% to $1.1 million in 2023, then skyrocketed by 962.55% to $11.7 million in 2024, then grew by 12.32% to $13.1 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $13.1 million, $11.7 million, and $1.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.